June 15, 2022
Life Sciences
  • A Food and Drug Administration (FDA) advisory panel voted 22-0 to recommend the agency expand the authorization of Moderna’s COVID-19 vaccine to children and teenagers ages 6 to 17. An FDA analysis estimated that the vaccine was 93 percent effective for teens and 77 percent effective for younger children. The FDA is likely to follow the panel’s advice in the coming days. However, since children and teenagers have had access to Pfizer-BioNTech’s vaccine since last year, the authorization won’t materially impact vaccination rates. (Articles here, here, here, here, here, and here)